Publication

Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients

Said, M. Y., Bollenbach, A., Minović, I., van Londen, M., Frenay, A-R., de Borst, M. H., van den Berg, E., Kayacelebi, A. A., Tsikas, D., van Goor, H., Navis, G. & Bakker, S. J. L., Jun-2019, In : Amino Acids. 51, 6, p. 913-927 15 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Said, M. Y., Bollenbach, A., Minović, I., van Londen, M., Frenay, A-R., de Borst, M. H., ... Bakker, S. J. L. (2019). Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients. Amino Acids, 51(6), 913-927. https://doi.org/10.1007/s00726-019-02725-2

Author

Said, M Yusof ; Bollenbach, A ; Minović, Isidor ; van Londen, Marco ; Frenay, Anne-Roos ; de Borst, Martin H ; van den Berg, Else ; Kayacelebi, A Arinc ; Tsikas, Dimitrios ; van Goor, Harry ; Navis, Gerjan ; Bakker, Stephan J L. / Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients. In: Amino Acids. 2019 ; Vol. 51, No. 6. pp. 913-927.

Harvard

Said, MY, Bollenbach, A, Minović, I, van Londen, M, Frenay, A-R, de Borst, MH, van den Berg, E, Kayacelebi, AA, Tsikas, D, van Goor, H, Navis, G & Bakker, SJL 2019, 'Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients', Amino Acids, vol. 51, no. 6, pp. 913-927. https://doi.org/10.1007/s00726-019-02725-2

Standard

Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients. / Said, M Yusof; Bollenbach, A; Minović, Isidor; van Londen, Marco; Frenay, Anne-Roos; de Borst, Martin H; van den Berg, Else; Kayacelebi, A Arinc; Tsikas, Dimitrios; van Goor, Harry; Navis, Gerjan; Bakker, Stephan J L.

In: Amino Acids, Vol. 51, No. 6, 06.2019, p. 913-927.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Said MY, Bollenbach A, Minović I, van Londen M, Frenay A-R, de Borst MH et al. Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients. Amino Acids. 2019 Jun;51(6):913-927. https://doi.org/10.1007/s00726-019-02725-2


BibTeX

@article{122a9c3cad404a16bf9d40a8428107d5,
title = "Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients",
abstract = "Cardiovascular disease (CVD) is the leading cause of death in renal transplant recipients (RTR). Elevated plasma asymmetric dimethylarginine (pADMA), an endogenous nitric oxide synthase inhibitor produced from the turnover of methylated arginine moieties in proteins, is a risk factor for CVD and mortality. It is unknown how urinary ADMA excretion (uADMA), one of the main ADMA elimination routes, is associated with long-term survival. Furthermore, the association of pADMA and uADMA with markers for turnover of arginine-methylated proteins is unknown. We analyzed ADMA using a validated GC-MS/MS method in plasma and 24-h urine samples of 685 RTR, included1year after transplantation. We also analyzed urine symmetric dimethylarginine (uSDMA) using the same method. Urinary creatinine and urea excretions were used as markers for turnover of muscle protein and amino acids, respectively. We applied Cox regression analyses to study associations of pADMA, uADMA, and uSDMA with all-cause and CVD mortality. Mean pADMA was 0.61 +/- 0.12 mu M, uADMA was 31 +/- 13 mu mol/24h, and uSDMA was 52 +/- 19 mu mol/24h. Over median follow-up of 5.4 [4.9-6.1] years, 147 RTR died, of which 58 (39{\%}) from CVD. High pADMA was associated with high all-cause mortality (HR per SD [95{\%} CI]: 1.45 [1.26-1.67], P",
keywords = "Kidney transplantation, ADMA, SDMA, Muscle mass, Protein turnover, Long-term survival, ASYMMETRIC DIMETHYLARGININE ADMA, ARGININE N-METHYLTRANSFERASE, NITRIC-OXIDE SYNTHASE, METHYL-ESTER, 7 PRMT7, PROTEIN, DISEASE, HUMANS, RISK, HYPERTENSION",
author = "Said, {M Yusof} and A Bollenbach and Isidor Minović and {van Londen}, Marco and Anne-Roos Frenay and {de Borst}, {Martin H} and {van den Berg}, Else and Kayacelebi, {A Arinc} and Dimitrios Tsikas and {van Goor}, Harry and Gerjan Navis and Bakker, {Stephan J L}",
year = "2019",
month = "6",
doi = "10.1007/s00726-019-02725-2",
language = "English",
volume = "51",
pages = "913--927",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "SPRINGER WIEN",
number = "6",

}

RIS

TY - JOUR

T1 - Plasma ADMA, urinary ADMA excretion, and late mortality in renal transplant recipients

AU - Said, M Yusof

AU - Bollenbach, A

AU - Minović, Isidor

AU - van Londen, Marco

AU - Frenay, Anne-Roos

AU - de Borst, Martin H

AU - van den Berg, Else

AU - Kayacelebi, A Arinc

AU - Tsikas, Dimitrios

AU - van Goor, Harry

AU - Navis, Gerjan

AU - Bakker, Stephan J L

PY - 2019/6

Y1 - 2019/6

N2 - Cardiovascular disease (CVD) is the leading cause of death in renal transplant recipients (RTR). Elevated plasma asymmetric dimethylarginine (pADMA), an endogenous nitric oxide synthase inhibitor produced from the turnover of methylated arginine moieties in proteins, is a risk factor for CVD and mortality. It is unknown how urinary ADMA excretion (uADMA), one of the main ADMA elimination routes, is associated with long-term survival. Furthermore, the association of pADMA and uADMA with markers for turnover of arginine-methylated proteins is unknown. We analyzed ADMA using a validated GC-MS/MS method in plasma and 24-h urine samples of 685 RTR, included1year after transplantation. We also analyzed urine symmetric dimethylarginine (uSDMA) using the same method. Urinary creatinine and urea excretions were used as markers for turnover of muscle protein and amino acids, respectively. We applied Cox regression analyses to study associations of pADMA, uADMA, and uSDMA with all-cause and CVD mortality. Mean pADMA was 0.61 +/- 0.12 mu M, uADMA was 31 +/- 13 mu mol/24h, and uSDMA was 52 +/- 19 mu mol/24h. Over median follow-up of 5.4 [4.9-6.1] years, 147 RTR died, of which 58 (39%) from CVD. High pADMA was associated with high all-cause mortality (HR per SD [95% CI]: 1.45 [1.26-1.67], P

AB - Cardiovascular disease (CVD) is the leading cause of death in renal transplant recipients (RTR). Elevated plasma asymmetric dimethylarginine (pADMA), an endogenous nitric oxide synthase inhibitor produced from the turnover of methylated arginine moieties in proteins, is a risk factor for CVD and mortality. It is unknown how urinary ADMA excretion (uADMA), one of the main ADMA elimination routes, is associated with long-term survival. Furthermore, the association of pADMA and uADMA with markers for turnover of arginine-methylated proteins is unknown. We analyzed ADMA using a validated GC-MS/MS method in plasma and 24-h urine samples of 685 RTR, included1year after transplantation. We also analyzed urine symmetric dimethylarginine (uSDMA) using the same method. Urinary creatinine and urea excretions were used as markers for turnover of muscle protein and amino acids, respectively. We applied Cox regression analyses to study associations of pADMA, uADMA, and uSDMA with all-cause and CVD mortality. Mean pADMA was 0.61 +/- 0.12 mu M, uADMA was 31 +/- 13 mu mol/24h, and uSDMA was 52 +/- 19 mu mol/24h. Over median follow-up of 5.4 [4.9-6.1] years, 147 RTR died, of which 58 (39%) from CVD. High pADMA was associated with high all-cause mortality (HR per SD [95% CI]: 1.45 [1.26-1.67], P

KW - Kidney transplantation

KW - ADMA

KW - SDMA

KW - Muscle mass

KW - Protein turnover

KW - Long-term survival

KW - ASYMMETRIC DIMETHYLARGININE ADMA

KW - ARGININE N-METHYLTRANSFERASE

KW - NITRIC-OXIDE SYNTHASE

KW - METHYL-ESTER

KW - 7 PRMT7

KW - PROTEIN

KW - DISEASE

KW - HUMANS

KW - RISK

KW - HYPERTENSION

U2 - 10.1007/s00726-019-02725-2

DO - 10.1007/s00726-019-02725-2

M3 - Article

VL - 51

SP - 913

EP - 927

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

IS - 6

ER -

ID: 79043387